Key result
Confirmed iron deficiency anemia in hospitalized HF is linked to higher readmission and mortality.
Why the study?
Iron deficiency anemia and CKD are common comorbidities in patients with HF that may contribute to recurrent hospitalization and mortality, but data from Somali clinical settings remain limited.
Is membership in an anemia and complete iron-profile tested cohort associated with higher hospital readmission and mortality compared with an untested comparator cohort in patients hospitalized with heart failure in Somalia?
Cohort (n=298)
No
Is membership in an anemia and complete iron-profile tested cohort associated with higher hospital readmission and mortality compared with an untested comparator cohort in patients hospitalized with heart failure in Somalia?
In hospitalized heart failure patients in Somalia, those undergoing complete iron-profile testing for anemia had a 74.5% prevalence of confirmed iron deficiency anemia and experienced higher readmission and mortality rates, driven largely by multimorbidity, CKD, and selective testing.
Answers are grounded in this paper and cite their sources.
Anemia testing identifies multimorbid HF patients at elevated readmission risk; leaves open whether iron deficiency independently drives outcomes.
Background Iron deficiency anemia (IDA) and chronic kidney disease (CKD) are common comorbidities in patients with heart failure (HF) and may contribute to recurrent hospitalization and mortality. However, data from Somali clinical settings remain limited. This study evaluated adverse outcomes among hospitalized patients with HF who had anemia and complete iron-profile testing compared with an untested comparator HF cohort without complete iron-profile testing, and examined confirmed IDA within the tested cohort. Methods This retrospective cohort study was conducted at Mogadishu Somali Turkey Recep Tayyip Erdogan Training and Research Hospital, Mogadishu, Somalia. A total of 298 patients with HF were analyzed, including 149 patients in the HF anemia/iron-profile cohort and 149 patients in a comparator HF cohort without complete iron-profile testing. The comparator cohort should therefore be interpreted as an untested HF comparator group rather than a confirmed non-anemic or non–iron-deficient control group. Confirmed IDA was defined as anemia based on sex-specific hemoglobin thresholds together with ferritin <100 ng/mL or ferritin 100–299 ng/mL with transferrin saturation < 20%. The primary outcome was any recorded hospital readmission. Secondary outcomes included recurrent rehospitalization burden and mortality. Multivariable logistic regression was used to evaluate associations with readmission and mortality, while count regression analysis was used to evaluate recurrent rehospitalization burden. Results Among the 149 patients in the HF anemia/iron-profile cohort, all had anemia and 111 (74.5%) met HF-specific criteria for confirmed IDA. Compared with the untested comparator HF cohort, patients in the HF anemia/iron-profile cohort had significantly lower hemoglobin and mean corpuscular volume values, higher red cell distribution width, and higher prevalences of hypertension, diabetes mellitus, coronary artery disease, and CKD. The HF anemia/iron-profile cohort also demonstrated significantly higher rates of readmission, recurrent rehospitalization, and mortality. In adjusted analyses, membership in the HF anemia/iron-profile cohort was associated with higher readmission and mortality, although these associations should be interpreted cautiously because of selective iron-profile testing, baseline clinical differences, and non-contemporaneous cohort periods. Readmission and recorded CKD were associated with mortality in the adjusted model. Within the anemia/iron-profile cohort, confirmed IDA was associated with significantly lower ferritin, transferrin saturation, and serum iron levels; however, it was not significantly associated with readmission or mortality in the unadjusted within-cohort comparison. Conclusion Patients in the HF anemia/iron-profile cohort had substantially higher rates of readmission, recurrent rehospitalization, and mortality compared with the untested comparator HF cohort. Although confirmed IDA was highly prevalent, adverse outcomes appeared to be driven by the broader burden of anemia, selective iron-profile testing, CKD, recurrent hospitalization, and multimorbidity rather than the isolated prognostic effect of confirmed IDA alone. Routine iron-profile assessment may help identify high-risk patients with HF, but prospective studies with universal iron testing and standardized follow-up are needed.
No takes yet. Share an insight, caveat, or question.
Abdi et al. (2026) conducted a cohort in Hospitalized heart failure (n=298). Anemia with complete iron-profile testing (74.5% confirmed iron deficiency anemia) vs. Untested comparator heart failure cohort without complete iron-profile testing was evaluated on Any recorded hospital readmission. Anemia with complete iron-profile testing in hospitalized HF patients was associated with higher hospital readmission and mortality than an untested HF cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: